"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival

"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival Shares of Novo Nordisk A/S plummeted again on Monday after the company reported trial results showing its next-generation obesity shot, CagriSema, delivered 20.2% weight loss at 84 weeks, compared to 23.6% for Eli Lilly & Co.’s tirzepatide (Zepbound). Bloomberg Intelligence analyst Michael Shah explained, "This outcome is the worst-case scenario for Novo and heightens the need for M&A with Novo’s other GLP-1/Amylin drug." Shares of Novo in Copenhagen plunged as much as 16.5%, breaking below a support level...